KR900701274A - 남용 가능성을 감소시킨 용량 제형 - Google Patents

남용 가능성을 감소시킨 용량 제형

Info

Publication number
KR900701274A
KR900701274A KR1019900701415A KR900701415A KR900701274A KR 900701274 A KR900701274 A KR 900701274A KR 1019900701415 A KR1019900701415 A KR 1019900701415A KR 900701415 A KR900701415 A KR 900701415A KR 900701274 A KR900701274 A KR 900701274A
Authority
KR
South Korea
Prior art keywords
abuse
substance
antagonist
skin
release device
Prior art date
Application number
KR1019900701415A
Other languages
English (en)
Other versions
KR0142205B1 (en
Inventor
은 수 리
빅터 괴츠
Original Assignee
에드워드 엘. 맨델
알자 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에드워드 엘. 맨델, 알자 코포레이션 filed Critical 에드워드 엘. 맨델
Publication of KR900701274A publication Critical patent/KR900701274A/ko
Application granted granted Critical
Publication of KR0142205B1 publication Critical patent/KR0142205B1/ko

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
    • B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
    • B09B3/00—Destroying solid waste or transforming solid waste into something useful or harmless
    • B09B3/0075—Disposal of medical waste
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
    • B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
    • B09B2101/00—Type of solid waste
    • B09B2101/65—Medical waste
    • B09B2101/68—Transdermal patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Environmental & Geological Engineering (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

남용 가능성을 감소시킨 용량 제형
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 본 발명의 실시태양의 개략단면도이고,
제2도는 본 발명의 추가 실시 태양의 개략단면도이고,
제3도는 본 발명의 추가 실시태양의 개략단면도이고,
제4도는 본 발명의 추가 실시태양의 개략단면도이다.

Claims (13)

  1. A)도포하고자 하는 피부 또는 점막에 투과성인 형태의 남용성 물질 일정량과 B)도포하고자 하는 피부 또는 점막에 불투과성인 형태의 남용 무효량의 상기 남용성 물질에 대한 적어도 하나의 길항제의 혼합물을 함유함을 특징으로 하는 피부 또는 점막에 도포함으로써 남용성 물질을 투여하기 위한 남용 가능성을 감소시킨 조성물.
  2. 제1항에 있어서, 상기 남용성 물질과 길항제가 분산되어 있는 제약상 허용되는 담체를 추가로 함유하는 것을 특징으로 하는 조성물.
  3. 제1항에 있어서, 상기 길항제가 불투과성 형태의 날록손, 날트렉손. 날부핀 및 레벨로르판의 군 중에서 선택되는 것을 특징으로 하는 조성물.
  4. 제1항에 있어서, 상기 길항제가 날록손인 것을 특징으로 하는 조성물.
  5. A)남용성 물질이 인체에 방출되기 위해 통과되는 남용성 물질 방출장치, 및 B) i)상기 방출 장치를 통해서 인체로 방출될 수 있는 형태로 상기 저장약물 내에 존재하는 상기 남용성 물질과 ii)상기 방출 장치를 통해서 방출될 수 없는 형태로 상기 저장 약물내에 존재하는 남용 무효량의 상기 남용성 물질에 대한 적어도 하나의 길항제의 혼합물온 함유하고 상기 방출 장치에 의해 인체로부터 분리된 저장약물로 되어 있는 남용 가능성을 감소시킨, 남용성 물질의 인체 투여용 용량 제형.
  6. 제5항에 있어서, 상기 방출 장치가 물에 투과성이고 상기 남용성 물질과 길항제에는 불투과성인 반투과성 물질을 함유하고, 상기 저장 약물이 수용성 형태의 상기 남용성 물질 및 수불용성 헝태의 상기 길항제를 함유하며 반투과성 물질은 상기 남용성 물질의 용액에 배술 장치를 제공하는 것을 특징으로 하는 용량 제형.
  7. 제5항에 있어서, 상기 방출 장치가 상기 남용성 물질에 투과성이고 상기 길항제에 불투과성인 것을 특징으로 하는 용량 제형.
  8. A)남용성 물질이 피부 또는 점막에 방출되기 위해 통과되는 남용성 물질 방출 장치, B) i)상기 방출 장치를 통해서 피부에 방출될 수 있는 형태로 상기 저장 약물 내에 존재하는 상기 남용성 물질과 ii)상기 방출 장치를 통해서 피부에 방출될 수 없는 형태로 상기 저장 약물 내에 존재하는 남용 무효량의 상기 남용성 물질에 대한 적어도 하나외 길항제의 혼합물을 함유하고 상기 방출 장치에 의해 피부 또는 점막으로부터 분리된 저장약물, C)상기 저장 약물이 퍼부 또는 점막에 대한 남용성 물질의 방출 관계를 유지하도록 하는 장치로 되어있는 남용 가능성을 감소시킨 피부 또는 점막을 통한 남용성 물질 투여용 용량 제형.
  9. 제8항에 있어서, 상기 방출 장치가 물에 투과성이고 상기 남용성 물질과 길항제에는 불투과성인 반투과성 물질을 함유하고, 상기 저장 약물이 수용성 형태의 상기 남용성 물질 및 수불용성 형태의 상기 길항제를 함유하며, 반투과성 물질은 상기 남용성 물질의 용액에 배출 장치를 제공하는 것을 특징으로 하는 용탕 제형.
  10. 재8항에 있어서, 상기 방출 장치가 상기 남용성 물질에 투과성이고 상기 길항제에 불투과성인 것을 륵징으로 하는 용량 제형.
  11. (A) i)도포하고자 하는 피부 또는 점막에 투과성인 형태의 남용성 물질 일정량과 ii)도포하고자 하는 피부 또는 절막에 불투과성인 형태의 남용무효량의 상기 남용성 물질에 대한 적어도 하나의 길항제의 혼합물을 함유하는 조성물을 피부 또는 점막에 접촉시키고, (B)적어도 유리한 효과를 얻는데 충분한 기간 동안 피부 또는 점막에 상기 조성물을 유지시키는 것을 포함한 남용성 물질을 피부 또는 점막에 투여하여 예정된 유리한 효과를 얻는 것을 특징으로 하는 투여 방법.
  12. (A)인체에 대한 남용성 물질 전달 관계 내에의 일정량의 남용성 물질과 남응 무효량의 상기 남용성 물질에 대한 적어도 하나의 길항제를 함유한 용량제형을 위치시키고, 7)상기 남용성 물질을 상기 용량 제형으로부터 인체에 전달시키고 (C)상기 용량 제형내에 상기 길항제를 보유하는 것으로 되어 있는 남용 가능성을 감소시킨 용량 제형으로부터 남용성 물질을 인체에 투여하는 방법.
  13. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR90701415A 1988-11-01 1990-07-02 Dosage form having reduced abuse potential KR0142205B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/265,738 US5236714A (en) 1988-11-01 1988-11-01 Abusable substance dosage form having reduced abuse potential
US265.738 1988-11-01
PCT/US1989/004722 WO1990004965A1 (en) 1988-11-01 1989-10-23 Dosage form having reduced abuse potential

Publications (2)

Publication Number Publication Date
KR900701274A true KR900701274A (ko) 1990-12-01
KR0142205B1 KR0142205B1 (en) 1998-06-01

Family

ID=23011702

Family Applications (1)

Application Number Title Priority Date Filing Date
KR90701415A KR0142205B1 (en) 1988-11-01 1990-07-02 Dosage form having reduced abuse potential

Country Status (13)

Country Link
US (1) US5236714A (ko)
EP (1) EP0441833B1 (ko)
JP (1) JP2744102B2 (ko)
KR (1) KR0142205B1 (ko)
AU (1) AU621952B2 (ko)
CA (1) CA1336488C (ko)
DE (1) DE68909056T2 (ko)
ES (1) ES2017195A6 (ko)
GR (1) GR1000380B (ko)
IE (1) IE63251B1 (ko)
NZ (1) NZ231001A (ko)
PT (1) PT92166B (ko)
WO (1) WO1990004965A1 (ko)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
DE4423850A1 (de) * 1994-07-07 1996-01-11 Labtec Gmbh Transdermales therapeutisches System zur Applikation von Naloxon
US5656416A (en) * 1994-12-22 1997-08-12 Eastman Kodak Company Photographic processing composition and method using organic catalyst for peroxide bleaching agent
US6284266B1 (en) * 1995-07-28 2001-09-04 Zars, Inc. Methods and apparatus for improved administration of fentanyl and sufentanil
DE69709646T2 (de) * 1996-03-12 2002-08-14 Alza Corp Zusammensetzung und dosisform mit einem opioid-antagonisten
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
DE19743484C1 (de) * 1997-10-01 1999-01-28 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Schutz vor oraler Applikation und Verfahren zum Schutz einer Person vor Kontamination infolge unzulässiger oraler Applikation toxischer Inhaltsstoffe eines transdermalen therapeutischen Systems
US7011843B2 (en) * 1997-10-01 2006-03-14 Lts Lohmann-Therapie Systeme Ag Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
EP2266564B1 (en) 1997-12-22 2013-03-13 Euro-Celtique S.A. Pharmaceutical oral dosage form comprising a combination of an opioid agonist and an opioid antagonist
WO1999032120A1 (en) 1997-12-22 1999-07-01 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
DE19960154A1 (de) * 1999-12-14 2001-07-12 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur transmucosalen Verabreichung von Oxycodon oder einem vergleichbaren Wirkstoff in der Mundhöhle, für die Anwendung in der Schmerztherapie und Suchttherapie
ES2326730T3 (es) 2000-02-08 2009-10-19 Euro-Celtique S.A. Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas.
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
GB0026137D0 (en) * 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
EP2266719B1 (en) * 2001-04-23 2016-06-08 Euro-Celtique S.A. Disposal system for transdermal dosage form
EP2062573B1 (en) * 2001-05-01 2011-11-16 Euro-Celtique S.A. Abuse resistant opioid containing transdermal systems
EP1387673B1 (en) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Abuse-resistant controlled-release opioid dosage form
EP1418862A4 (en) * 2001-06-29 2010-06-09 Leon J Lewandowski INDIVIDUALIZED SEARCH THERAPY
EP1414458B1 (en) * 2001-07-06 2007-04-11 Endo Pharmaceuticals Inc. Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
KR20030048026A (ko) * 2001-07-06 2003-06-18 펜웨스트 파머슈티칼즈 컴파니 옥시모르폰의 서방형 제제
DK1416842T3 (da) 2001-07-18 2009-03-16 Euro Celtique Sa Farmaceutiske kombinationer af oxycodon og naloxon
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
DE60232417D1 (de) 2001-08-06 2009-07-02 Euro Celtique Sa Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20030068276A1 (en) 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
EP1429730A4 (en) * 2001-09-26 2010-06-16 Penwest Pharmaceuticals Compan OPIOID FORMULATIONS WITH REDUCED ABUSE POTENTIAL
WO2003032926A2 (en) * 2001-10-19 2003-04-24 Memorial Sloan-Kettering Cancer Center Compositions and methods for reversal of drug resistance
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
NZ535286A (en) * 2002-04-05 2007-07-27 Euro Celtique Sa Matrix for sustained, invariant and independent release of active compounds
JP2005526839A (ja) * 2002-04-23 2005-09-08 アルザ・コーポレーシヨン 不正使用の可能性が低い経皮鎮痛薬システム
AU2003240493B2 (en) * 2002-05-31 2008-06-12 L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Implantable polymeric device for sustained release of buprenorphine
EP1837023A1 (en) * 2002-06-10 2007-09-26 Euro-Celtique S.A. Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein
ATE423560T1 (de) * 2002-08-20 2009-03-15 Euro Celtique Sa Transdermale dosierungsform enthaltend einen wirkstoff und einen antagonisten in freier base und in salz form
CA2498798A1 (en) * 2002-09-20 2004-04-01 Alpharma, Inc. Sustained-release opioid formulations and methods of use
CA2499550C (en) 2002-09-20 2013-10-15 Alpharma, Inc. Sequestering subunit and related compositions and methods
GB0300531D0 (en) * 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
JP2006520392A (ja) * 2003-03-13 2006-09-07 コントロールド・ケミカルズ・インコーポレーテッド 薬物の乱用可能性を低下させ且つ作用持続時間を延長する化合物および方法
DE602004031512D1 (de) * 2003-03-31 2011-04-07 Titan Pharmaceuticals Inc Polymeres implantat zur verzögerten freisetzung von dopamin antagonisten
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
US7182955B2 (en) * 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
CA2522529C (en) 2003-04-30 2015-10-20 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US20040219195A1 (en) * 2003-04-30 2004-11-04 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US8906413B2 (en) * 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US20080020028A1 (en) * 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
JP2007527415A (ja) * 2003-10-30 2007-09-27 アルザ・コーポレーシヨン 乱用の可能性が低い経皮鎮痛剤システム
US7867511B2 (en) * 2004-01-23 2011-01-11 Travanti Pharma Inc. Abuse potential reduction in abusable substance dosage form
US8535711B2 (en) * 2004-01-23 2013-09-17 Teikoku Pharma Usa, Inc. Medication disposal system
SI1718258T1 (sl) 2004-02-23 2009-08-31 Euro Celtique Sa Naprava za transdermalno dajanje opioida, varna pred zlorabo
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20070269522A1 (en) * 2004-08-20 2007-11-22 Wold Chad R Transdermal Drug Delivery Device with Translucent Protective Film
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US7226619B1 (en) 2004-09-07 2007-06-05 Pharmorx Inc. Material for controlling diversion of medications
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
AU2005284908B2 (en) 2004-09-13 2011-12-08 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
JP5046946B2 (ja) * 2004-10-15 2012-10-10 スパーナス ファーマシューティカルズ インコーポレイテッド 低乱用性薬学的製剤
US8246977B2 (en) 2004-10-21 2012-08-21 Durect Corporation Transdermal delivery systems
US8252319B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
US7827983B2 (en) * 2004-12-20 2010-11-09 Hewlett-Packard Development Company, L.P. Method for making a pharmaceutically active ingredient abuse-prevention device
EA015615B1 (ru) * 2005-01-28 2011-10-31 Еуро-Селтик С.А. Устойчивые к спиртам лекарственные формы
TW200640526A (en) * 2005-02-24 2006-12-01 Alza Corp Transdermal electrotransport drug delivery systems with reduced abuse potential
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US20060223786A1 (en) * 2005-04-01 2006-10-05 Smith David J Transdermal pain control method and device
DE602006016441D1 (de) * 2005-05-13 2010-10-07 Alza Corp Mehrlagiges arzneimittelausbringsystem mit sperre gegen reservoirmaterialfluss
CA2629046C (en) * 2005-12-13 2014-04-08 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9066847B2 (en) * 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US9289583B2 (en) 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8357114B2 (en) * 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US7740879B2 (en) * 2006-01-17 2010-06-22 Harrogate Holdings Abuse resistant transdermal drug delivery patch
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
JP5457830B2 (ja) 2006-04-03 2014-04-02 オディディ，イサ オルガノゾル被膜を含む制御放出送達デバイス
US20070248657A1 (en) * 2006-04-25 2007-10-25 Smith David J Multi-compartment transdermal pain control device
US20070260491A1 (en) * 2006-05-08 2007-11-08 Pamela Palmer System for delivery and monitoring of administration of controlled substances
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
DE102006025282A1 (de) 2006-05-31 2007-12-20 Lts Lohmann Therapie-Systeme Ag Selbstzerstörendes transdermales therapeutisches System
US20070278289A1 (en) * 2006-05-31 2007-12-06 Toshiba Tec Kabushiki Kaisha Payment adjusting apparatus and program therefor
PT2484346T (pt) 2006-06-19 2017-04-26 Alpharma Pharmaceuticals Llc Composições farmacêuticas
US20070299687A1 (en) * 2006-06-23 2007-12-27 Pamela Palmer Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed
WO2008011194A2 (en) 2006-07-21 2008-01-24 Biodelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
US20090048237A1 (en) * 2007-08-07 2009-02-19 Acelrx Pharmaceuticals, Inc. Compositions and methods for procedural sedation and analgesia using oral transmucosal dosage forms
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
US9700552B2 (en) 2008-02-28 2017-07-11 Syntropharma Limited Pharmaceutical compositions for treatment of addiction
EP2254561A2 (en) * 2008-03-26 2010-12-01 AllTranz Inc. Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
DE102008016804B4 (de) 2008-04-02 2012-01-05 Lts Lohmann Therapie-Systeme Ag Selbstzerstörendes transdermales therapeutisches System mit verbesserter Funktionalität und Wirksamkeit sowie seine Verwendung
ES2663777T3 (es) * 2008-06-23 2018-04-17 Biodelivery Sciences International, Inc. Dispositivos de administración mucosa multidireccionales y métodos de uso
US8945592B2 (en) * 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
US20100221313A1 (en) * 2008-12-01 2010-09-02 Innovative Pharmaceuticals, Llc Transdermal reservoir patch
TR201900199T4 (tr) 2009-03-10 2019-02-21 Euro Celtique Sa Oksikodon ve nalokson içeren çabuk salımlı farmasötik bileşimler.
DE102009036485B4 (de) 2009-08-07 2012-10-04 Lts Lohmann Therapie-Systeme Ag Mittel zur zerstörenden Entsorgung von medizinischen Wirkstoffen in transdermalen therapeutischen Systemen
US20110091544A1 (en) * 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
WO2011112956A1 (en) * 2010-03-12 2011-09-15 Government Of The Usa, As Represented By The Sec., Dept. Of Health And Human Services Agonist/antagonist compositions and methods of use
WO2011130455A1 (en) 2010-04-13 2011-10-20 Najib Babul Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use
EP2707032B1 (en) * 2011-05-10 2019-06-26 Antecip Bioventures II LLC Implantable polymeric device for sustained release of sufentanil
EP2729148A4 (en) 2011-07-06 2015-04-22 Parkinson S Inst COMPOSITIONS AND METHODS FOR TREATING SYMPTOMS IN PATIENTS WITH PARKINSON'S DISEASE
SG11201401446RA (en) 2011-08-18 2014-09-26 Biodelivery Sciences Int Inc Abuse-resistant mucoadhesive devices for delivery of buprenorphine
RU2014108664A (ru) 2011-09-30 2015-11-10 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Общая система утилизации лекарственных средств
US8790583B2 (en) 2011-09-30 2014-07-29 Teikoku Pharma Usa, Inc. Transdermal patch disposal system
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
MY183489A (en) 2013-07-23 2021-02-22 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US10010543B1 (en) 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
AU2016211330A1 (en) 2015-01-28 2017-08-03 Chrono Therapeutics Inc. Drug delivery methods and systems
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
US11285306B2 (en) 2017-01-06 2022-03-29 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
US11389844B2 (en) 2018-03-20 2022-07-19 Verde Environmental Technologies, Inc. Blister pack disposal system
EP3801732A4 (en) 2018-05-29 2022-04-27 Morningside Venture Investments Limited DRUG DELIVERY METHODS AND SYSTEMS
WO2020008366A1 (en) 2018-07-02 2020-01-09 Clexio Biosciences Ltd. Transdermal dosage form
WO2020008370A1 (en) 2018-07-02 2020-01-09 Clexio Biosciences Ltd. Transdermal patch
WO2020009685A1 (en) 2018-07-02 2020-01-09 John Tang Transdermal dosage form
AU2020226862B2 (en) * 2019-02-21 2021-11-11 Pharmaceutical Productions, Inc. Naloxone formulations for sublingual and/or buccal administration

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3493657A (en) * 1961-03-14 1970-02-03 Mozes Juda Lewenstein Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine
US3993073A (en) * 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3773955A (en) * 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4366159A (en) * 1981-09-08 1982-12-28 Michael Richard Magruder Nalbuphine-narcotic analgesic composition and method of producing analgesia
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4588580B2 (en) * 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4573995A (en) * 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US4655766A (en) * 1985-08-01 1987-04-07 Alza Corporation Fluid imbibing pump with self-regulating skin patch

Also Published As

Publication number Publication date
JPH04501412A (ja) 1992-03-12
IE893455L (en) 1990-05-01
US5236714A (en) 1993-08-17
JP2744102B2 (ja) 1998-04-28
KR0142205B1 (en) 1998-06-01
IE63251B1 (en) 1995-04-05
GR1000380B (el) 1992-06-30
ES2017195A6 (es) 1991-01-01
PT92166B (pt) 1995-09-12
NZ231001A (en) 1991-11-26
AU4500489A (en) 1990-05-28
WO1990004965A1 (en) 1990-05-17
EP0441833A1 (en) 1991-08-21
DE68909056T2 (de) 1994-01-05
GR890100636A (en) 1990-12-31
AU621952B2 (en) 1992-03-26
EP0441833B1 (en) 1993-09-08
PT92166A (pt) 1990-05-31
DE68909056D1 (de) 1993-10-14
CA1336488C (en) 1995-08-01

Similar Documents

Publication Publication Date Title
KR900701274A (ko) 남용 가능성을 감소시킨 용량 제형
US4597961A (en) Transcutaneous application of nicotine
US4810499A (en) Transdermal drug delivery system and method
US6319510B1 (en) Gum pad for delivery of medication to mucosal tissues
US5665378A (en) Transdermal therapeutic formulation
KR890011585A (ko) 경피식 피임약제제형
ATE173162T1 (de) Medizinische vorrichtung zur verabreichung von aktivsubstanzen oder arzneistoffen in sehr niedriger dosis, insbesondere von homöopatischen arzneistoffen
GB2316004A (en) Novel formulations for transdermal delivery of pergolide
DE3650189D1 (de) Mittel zur nichsystemischen Verabreichung von Sedativa und Analgetika.
KR870003798A (ko) 생물학적 활성물질을 박동식으로 경피투여하는 의료장치
PT100502A (pt) Composicoes farmaceuticas para aumentar a capacidade de permeacao na pele utilizando monolinoleato de glicerol
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
CY2503B1 (en) Novel formulations for the transdermal administration of fluoxetine acetate and fluoxetine maleate.
WO2006053222A2 (en) Instant patch for dermal drug delivery
ES2021028B3 (es) Dispositivo para liberacion de farmacos en 2 etapas.
US20020127271A1 (en) Formulation for the treatment and/or prophylaxis of dementia
US4476115A (en) Analgesic composition and method of treating subdermal pain
WO2003030793A1 (en) Hydrating nasal gel and applicator
KR910021238A (ko) 켈로이드 치료제
KR890007728A (ko) 진통제 제조방법
KR20000029523A (ko) 치매치료및(또는)예방용제제
KR880002537A (ko) 생약제제
JPS633844B2 (ko)
KR910005856A (ko) 호흡기 질환 치료용 제약 조성물
TH18426B (th) การปล่อยส่วนผสมยาแข็ง

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee